Welcome to our dedicated page for Quanterix SEC filings (Ticker: QTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Quanterix's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Quanterix's regulatory disclosures and financial reporting.
Quanterix Corporation announced that Chief Financial Officer and Treasurer Vandana Sriram will leave the company, with her role ending on June 15, 2026. She will stay through that date to support a smooth transition while the company conducts a search for her successor with an executive search firm.
Under her employment agreement, Ms. Sriram will receive 12 months of base salary, an amount equal to her annual target bonus for 2026, and subsidized health benefits for 12 months. The company states that her departure is not related to any disagreements regarding accounting practices, financial statements, internal controls, or operations, and highlights that Quanterix remains on solid financial footing with a focus on cash flow breakeven and synergy targets.
Ameriprise Financial, Inc. filed an Amendment No. 6 to a Schedule 13G/A reporting shared voting and dispositive power over 990,224 shares of Quanterix Corp common stock, representing 2.1% of the class. The filing lists Quanterix's principal executive office at 900 Middlesex Turnpike, Billerica, MA and states that AFI disclaims beneficial ownership of the reported shares.
Quanterix Corporation reported higher revenue but a mixed bottom line for the quarter ended March 31, 2026. Total revenue rose to $36.4 million from $30.3 million, driven by the 2025 acquisition of Akoya Biosciences, which contributed $8.7 million of product revenue and $3.7 million of service revenue. Legacy Quanterix product revenue fell as U.S. federal research funding cuts and macro-economic pressures reduced consumables demand and Accelerator Laboratory volumes.
Gross profit increased slightly to $15.6 million, but the gross margin declined to 43%, and the operating loss widened to $41.4 million due to a $19.3 million impairment of in‑process R&D tied to a terminated Akoya diagnostic development agreement. That termination also generated $21.6 million of one-time other income. Net loss improved to $17.5 million, or $0.37 per share. Quanterix ended the quarter with $36.2 million in cash and cash equivalents and $63.1 million in marketable securities and continues to target cash flow breakeven in the second half of 2026 while advancing its Alzheimer’s diagnostics strategy, including a 510(k) submission for a multi‑analyte blood test and Medicare pricing of $897 for its LucentAD Complete test.
Quanterix Corporation reported first-quarter 2026 revenue of $36.4 million, up 20% from $30.3 million a year earlier, driven by product and service growth across its Simoa and spatial biology platforms. GAAP gross margin was 42.7%, while adjusted gross margin improved to 50.9% from 49.7%.
The company posted a GAAP net loss of $17.5 million (or $0.37 per share), modestly better than the $20.5 million loss in 2025, and an adjusted EBITDA loss of $9.8 million versus $11.3 million. Quanterix ended the quarter with $102.6 million in cash, cash equivalents, marketable securities and restricted cash.
Management highlighted progress on integrating Akoya Biosciences, citing $85 million of cost synergies realized and a terminated off-market diagnostics contract that drove significant one-time charges and income. The Alzheimer’s diagnostics franchise continues to expand, with several clinical utility studies expected to complete and an FDA decision on a 510(k) application anticipated in the second half of 2026.
For full-year 2026, Quanterix reaffirmed revenue guidance of $169–$174 million, GAAP gross margin of 41–45% and adjusted gross margin of 49–53%. The company continues to expect cash flow breakeven in the second half of 2026 and to finish the year with roughly $100 million in cash and no debt.
Quanterix Corp Chief Operating Officer Michael Francis Miller reported routine equity compensation activity. He exercised 130 restricted stock units that converted into 130 shares of common stock on a one-for-one basis. To cover tax obligations, 39 common shares were disposed of through a tax-withholding transaction, not an open-market sale.
Following these transactions, Miller directly holds 32,613 shares of common stock and 549 restricted stock units that remain outstanding from a prior grant of 6,278 RSUs made on September 23, 2022.
Quanterix Corporation is holding its 2026 annual stockholder meeting virtually at 10:00 a.m. ET on June 9, 2026 via meetnow.global/QTRX2026. Holders of common stock as of April 14, 2026, when 47,064,988 shares were outstanding, may vote.
Stockholders will vote on electing two directors to one-year terms, an advisory approval of named executive officer compensation, an advisory ratification of KPMG LLP as independent auditor for 2026, and approval of an amended and restated 2017 Employee, Director and Consultant Equity Incentive Plan, plus any other properly presented business.
Quanterix Corp Chief Operating Officer Michael Francis Miller exercised restricted stock units into common stock and had shares withheld to cover taxes. On April 15, 2026, he acquired a total of 1,558 shares of common stock through multiple RSU conversions, all at a stated price of $0.00 per share.
To satisfy tax obligations related to these vesting events, 467 shares of common stock were disposed of at $3.60 per share in tax-withholding transactions. Following these transactions, Miller directly held 32,522 shares of Quanterix common stock.
Quanterix Corp Chief Financial Officer Sriram Vandana reported routine equity compensation activity involving restricted stock units that converted into common stock. On April 15, 2026, restricted stock units converted into common stock on a one-for-one basis, delivering 263, 514 and 1,056 shares in separate tranches.
Related common stock entries show 263, 514 and 1,056-share acquisitions at a price of $0.00 per share. To satisfy tax obligations, 79, 154 and 315 shares of common stock were withheld at $3.60 per share as tax-withholding dispositions, rather than open-market sales.
Following these transactions, the filing shows Sriram Vandana directly holding 28,713 shares of Quanterix common stock. The derivative section lists no remaining restricted stock units tied to these specific conversions, underscoring that the reported activity reflects compensation vesting and associated tax withholding.
DONNELLY WILLIAM P reported acquisition or exercise transactions in this Form 4 filing.
Quanterix Corp Executive Chair William P. Donnelly received 6,178 shares of Common Stock as a stock grant. The shares were awarded at a stated price of $0.00 per share as a grant or award transaction, rather than an open-market purchase or sale.
According to the disclosure, this stock was granted in lieu of cash fees for Donnelly’s service on Quanterix’s Board of Directors and its committees for the first quarter of 2026. Following this award, Donnelly directly holds a total of 154,127 shares of Quanterix Common Stock.